No Known Mutations

IRB# 19388 A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

IRB# 19390 A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

IRB# 21194 study A phase 1 study of SGN-CD228A in select advanced solid tumors

IRB# 21508 Study of ORIC-101 in Combination With Anticancer Therapy

IRB# 21464 coming soon

IRB# 21766 A Phase I/b study of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy

IRB# 22082 coming soon

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view
### Phase I Program

**Note:** Other Phase 1 Studies may be open at the Knight, please click here to view

<table>
<thead>
<tr>
<th>Tumor Mutation</th>
<th>NTRK, ROS1, ALK</th>
<th>Fusion-NTRK</th>
<th>RET Mutations</th>
<th>Fusion Proteins Specific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burden - High</td>
<td>gene rearrangement</td>
<td>(previously treated)</td>
<td></td>
<td>BRD Amplifications Specific</td>
</tr>
<tr>
<td>IRB# 21548 A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors</td>
<td>IRB# 15206 Entrectinib in Patients with Advanced or Metastatic Solid Tumors</td>
<td>IRB# 16676 BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors</td>
<td>IRB# 18164 A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity</td>
<td>MYC Amplifications Specific</td>
</tr>
<tr>
<td>IRB# 18788 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)</td>
<td>IRB# 17674 Loxo-195 in fusion-NTRK (previously treated) solid tumors</td>
<td></td>
<td>AR Amplifications Specific</td>
<td></td>
</tr>
</tbody>
</table>

**Tumor Mutation Burden - High**

- NTRK, ROS1, ALK gene rearrangement
- IRB# 15206 Entrectinib in Patients with Advanced or Metastatic Solid Tumors
- IRB# 16676 BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors
- IRB# 18164 A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

**Folate Receptor Alpha Expression**

- TNBC, HGSOC, Endometrial, and advanced solid tumors with Tp53 mutation
- IRB 21349 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- IRB 21819 A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors
- IRB 21856 coming soon

**Folate Receptor Alpha Expression**

- TNBC, NSCLC, EC, OC

**Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway**

- CLDN18.2 expressing solid tumors

**Key**

- [ ] Open for Enrollment
- [ ] In Development
- [ ] Enrollment on Hold

2/12/2021

http://www.ohsu.edu/research/rda/so/knight.php
IRB 22223 coming soon

IRB 22580 coming soon

IRB 22680 coming soon

P53 Y220C mutations

No known mutation, phase 1; TREM1 expression phase 2

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

Solid Tumors likely to express ROR1

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php